specific DNA MMR defects, including MSH2 mutation and loss of protein expression, have been reported in high-risk patients. Given the increasing use of clofarabine in the treatment of elderly and other high-risk AML subgroups, our data suggest that DNA MMR status may be a relevant prognostic factor.
In summary, we have shown that DNA MMR status affects cellular response to the cytotoxic effects of nucleoside analogs, and these data suggest that the development of tailored chemotherapeutic regimens to exploit differences in DNA repair status could be of clinical use.
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We previously identified a 25-year-old man with AML (FAB M1) and a novel translocation that was initially described as a t(4;9)(q13;q34) by standard cytogenetic analysis but was subsequently revised to t(4;9)(q11;q33) following spectral karyotyping. The presence of BCR-ABL and DEK-CAN mRNA transcripts were both excluded by RT-PCR analysis. 4 To characterize the translocation in more detail, we initially performed split-apart interphase fluorescence in situ hybridization (FISH) analysis for genes that are known to be translocation targets in myeloid neoplasia. No rearrangements were seen with probes that flanked ABL at 9q34 or PDGFRA at 4q12; 5 however, split signals (not shown) were seen with bacterial artificial chromosome (BAC) clones RP11-525G7 and RP11-477J21 that were selected to flank CEP110, a gene encoding a centrosomal protein that is fused to FGFR1 in the 8p11 myeloproliferative syndrome with a t(8;9)(p12;q33). 6 Hypothesizing that the fusion partner was likely to be a tyrosine kinase, we next performed split apart FISH for the two other RTKs located at 4q12. No rearrangement was seen for KDR, but split signals were seen for KIT using BACs RP11-80L11 and RP11-273B19 (not shown).
CEP110 has multiple alternative transcripts, the longest of which is designated CEP110-010 (transcript identifier: ENST00000373855; 44 exons) and encodes a 2325-amino-acid protein. To determine if the t(4;9) resulted in a CEP110-KIT chimeric mRNA, we performed multiple RT-PCR analyses with a series of CEP110 forward primers and a reverse KIT primer located in the 5 0 portion of the region encoding the tyrosine kinase domain. As shown in Figure 1a , a specific product was amplified from patient cDNA but not from controls. Sequencing revealed an in-frame fusion of CEP110 exon 19 (exon identifier ENSE00001630413) to KIT exon 11 (KIT-001; transcript identifier ENST00000288135; exon identifier ENSE00001074417). The fusion (Figure 1b) is predicted to encode a 1384-amino-acid protein of 159 kDa that includes multiple potential oligomerization motifs derived from CEP110 and the tyrosine kinase domain of KIT. This structure is typical of tyrosine kinase fusions and, although we did not perform functional analysis, it is highly likely that CEP110-KIT is constitutively active and had an important role in driving the disease process.
The patient was successfully treated by allogeneic stem cell transplantation from an HLA-identical sibling and the patient remains in complete remission.
Systemic mastocytosis (SM) may be associated in up to 30% with a non-mast cell haematological disease leading to the separation of a peculiar subtype designated SM with associated haematological non-mast cell disease, which is commonly a Philadelphia chromosome/BCR-ABL-negative (Ph À ) myeloid neoplasm. 1 Criteria for the diagnosis of SM comprise one major finding (compact infiltrates consisting of 415 clustered mast 
